Company Overview and News
Stop missing out on important events!
BioTech Capital Limited’s (ASX:BTC) wholly owned subsidiary BioImpact has extended its exclusive license and supply agreement with RLS Global AB to include two additional products.
Biotech Capital (ASX:BTC) has been granted a trading halt by the ASX, pending details of a capital raising.
LOS ANGELES, CA--(Marketwired - February 09, 2017) - ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that its President & CEO, Robert Berman, will present at the Biotech Capital Conference in London, England on February 21, 2017 at 10:30 am.
The company’s strategy is to make active investments in life science businesses and late-stage product development opportunities that will benefit from greater access to development capital. The new partnership is aimed at identifying and facilitating a range of new business opportunities with biotech and medtech companies on both sides of the Pacific. Dr. John Chiplin currently serves on the boards of Adalta, Batu Biologics, Benitec Biopharma, The Coma Research Institute and Sienna Cancer Diagnostics among others.
Biotech Capital Ltd (ASX:BTC) is a Pooled Development Fund that is actively assessing new investment opportunities in a variety of sectors.